MiNK Therapeutics (INKT) Competitors $7.30 -0.29 (-3.82%) As of 12:36 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. EXOZ, ATOS, IVVD, BHST, PROC, SGMT, IOBT, CABA, IMAB, and SAVAShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Exozymes (EXOZ), Atossa Therapeutics (ATOS), Invivyd (IVVD), BioHarvest Sciences (BHST), Procaps Group (PROC), Sagimet Biosciences (SGMT), IO Biotech (IOBT), Cabaletta Bio (CABA), I-Mab (IMAB), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Its Competitors Exozymes Atossa Therapeutics Invivyd BioHarvest Sciences Procaps Group Sagimet Biosciences IO Biotech Cabaletta Bio I-Mab Cassava Sciences Exozymes (NASDAQ:EXOZ) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, risk, media sentiment, valuation, dividends and profitability. Does the MarketBeat Community prefer EXOZ or INKT? MiNK Therapeutics received 17 more outperform votes than Exozymes when rated by MarketBeat users. CompanyUnderperformOutperformExozymesN/AN/AMiNK TherapeuticsOutperform Votes1777.27% Underperform Votes522.73% Do analysts recommend EXOZ or INKT? MiNK Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 413.70%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Exozymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exozymes 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor EXOZ or INKT? In the previous week, MiNK Therapeutics had 2 more articles in the media than Exozymes. MarketBeat recorded 4 mentions for MiNK Therapeutics and 2 mentions for Exozymes. Exozymes' average media sentiment score of 0.94 beat MiNK Therapeutics' score of 0.90 indicating that Exozymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exozymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiNK Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in EXOZ or INKT? 2.9% of MiNK Therapeutics shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is EXOZ or INKT more profitable? Company Net Margins Return on Equity Return on Assets ExozymesN/A N/A N/A MiNK Therapeutics N/A N/A -189.14% Which has better earnings & valuation, EXOZ or INKT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExozymesN/AN/AN/AN/AN/AMiNK TherapeuticsN/AN/A-$22.46M-$2.52-2.90 SummaryMiNK Therapeutics beats Exozymes on 7 of the 9 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.10M$3.11B$5.60B$8.62BDividend YieldN/A1.57%5.28%4.18%P/E Ratio-1.8733.1427.2520.00Price / SalesN/A468.68413.35158.30Price / CashN/A168.6838.2534.64Price / Book-1.403.437.124.70Net Income-$22.46M-$72.35M$3.24B$248.14M7 Day Performance0.43%7.30%2.71%2.48%1 Month Performance-3.95%17.78%8.93%6.15%1 Year Performance-24.29%-16.89%31.30%13.59% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics3.1367 of 5 stars$7.30-3.8%$37.50+413.7%-23.3%$29.10MN/A-1.8730Short Interest ↓Gap DownEXOZExozymesN/A$13.50+0.7%N/AN/A$112.97MN/A0.0029News CoverageGap DownATOSAtossa Therapeutics1.6401 of 5 stars$0.87+11.5%$7.13+722.0%-29.2%$111.97MN/A-3.948IVVDInvivyd3.8169 of 5 stars$0.93-0.5%$5.85+529.0%-46.4%$111.56M$36.69M-0.47100Positive NewsGap DownBHSTBioHarvest SciencesN/A$6.75+7.8%$13.67+102.5%N/A$110.87M$27.70M-5.40N/APositive NewsPROCProcaps GroupN/A$0.95-40.3%N/A-62.7%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeSGMTSagimet Biosciences2.3745 of 5 stars$3.49-1.7%$22.40+541.8%+24.8%$107.06M$2M-1.988News CoverageIOBTIO Biotech4.0512 of 5 stars$1.62+14.1%$9.33+476.1%+13.6%$106.73MN/A-1.1830Positive NewsShort Interest ↓Gap UpHigh Trading VolumeCABACabaletta Bio2.8991 of 5 stars$2.06+10.2%$20.33+887.1%-84.2%$104.53MN/A-0.9650Trending NewsAnalyst ForecastAnalyst RevisionIMABI-Mab3.3577 of 5 stars$1.28-2.3%$5.50+329.7%+33.9%$104.53M$3.27M0.00380News CoveragePositive NewsGap DownSAVACassava Sciences4.2777 of 5 stars$2.13+6.0%$54.50+2,458.7%-88.9%$102.90MN/A-1.5430Positive News Related Companies and Tools Related Companies Exozymes Competitors Atossa Therapeutics Competitors Invivyd Competitors BioHarvest Sciences Competitors Procaps Group Competitors Sagimet Biosciences Competitors IO Biotech Competitors Cabaletta Bio Competitors I-Mab Competitors Cassava Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
